Samsung Biologics will expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.   Samsung Biologics has been providing aseptic filling and lyophilization services since 2013 and has 25 product approvals from global regulatory bodies, including the FDA and EMA. In response to the forecasted increase in demand for aseptic filling, the company is making a strategic investment on its global capacity by ...